COVID-19 and Global Chronic Disease 2024: The Post-pandemic Era

A special issue of Diseases (ISSN 2079-9721).

Deadline for manuscript submissions: 31 December 2024 | Viewed by 2262

Special Issue Editors


E-Mail Website
Guest Editor
1. Associate Professor of Thoracic Surgery, A. Gemelli University Hospital Foundation IRCCS, I-00168 Rome, Italy
2. Department of Medicine and Translational Surgery, Catholic University of Rome, 00153 Roma, Italy
Interests: imaging in lung cancer; imaging in pleural and mediastinal tumors; PET CT scan in thoracic neoplasms
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Coronavirus disease 2019 (COVID-19) is the condition caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since 2020, the pandemic has influenced our lives in nearly every corner of the world, causing over 770 million confirmed cases and more than 7 million deaths globally. This global scenario changed ways to perform research and consider healthcare systems. In fact, the COVID-19 crisis emphasized the connections between research, clinical practice, and health policies. On 5 May 2023, more than three years after the pandemic had been declared, the World Health Organization ended the global emergency status for COVID-19; however, the end of the pandemic will not be the end of COVID-19. It is necessary to continue protecting the most vulnerable people against the disease and its complications, through routine vaccination. In this way, many pivotal points are open and need to be clarified.

Aim and Scope

This Special Issue, titled “COVID-19 and Global Chronic Disease 2024: the Post-Pandemic era”, aims to report the state of the art and the new challenges resulting from COVID-19. In particular, we want to discuss the therapies, vaccines, public health policies, and social aspects related to this disease. We invite eminent scholars and emerging researchers to submit high-level scientific articles, as indicated in the keywords below.

Prof. Dr. Ludovico Abenavoli
Prof. Dr. Filippo Lococo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pandemic
  • COVID-19
  • infection
  • therapy
  • disease
  • health
  • patients
  • healthcare
  • research

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

54 pages, 1074 KiB  
Review
Long COVID in Children, Adults, and Vulnerable Populations: A Comprehensive Overview for an Integrated Approach
by Valeria Calcaterra, Sara Zanelli, Andrea Foppiani, Elvira Verduci, Beatrice Benatti, Roberto Bollina, Francesco Bombaci, Antonio Brucato, Selene Cammarata, Elisa Calabrò, Giovanna Cirnigliaro, Silvia Della Torre, Bernardo Dell’osso, Chiara Moltrasio, Angelo Valerio Marzano, Chiara Nostro, Maurizio Romagnuolo, Lucia Trotta, Valeria Savasi, Valeria Smiroldo and Gianvincenzo Zuccottiadd Show full author list remove Hide full author list
Diseases 2024, 12(5), 95; https://doi.org/10.3390/diseases12050095 - 6 May 2024
Viewed by 1909
Abstract
Long COVID affects both children and adults, including subjects who experienced severe, mild, or even asymptomatic SARS-CoV-2 infection. We have provided a comprehensive overview of the incidence, clinical characteristics, risk factors, and outcomes of persistent COVID-19 symptoms in both children and adults, encompassing [...] Read more.
Long COVID affects both children and adults, including subjects who experienced severe, mild, or even asymptomatic SARS-CoV-2 infection. We have provided a comprehensive overview of the incidence, clinical characteristics, risk factors, and outcomes of persistent COVID-19 symptoms in both children and adults, encompassing vulnerable populations, such as pregnant women and oncological patients. Our objective is to emphasize the critical significance of adopting an integrated approach for the early detection and appropriate management of long COVID. The incidence and severity of long COVID symptoms can have a significant impact on the quality of life of patients and the course of disease in the case of pre-existing pathologies. Particularly, in fragile and vulnerable patients, the presence of PASC is related to significantly worse survival, independent from pre-existing vulnerabilities and treatment. It is important try to achieve an early recognition and management. Various mechanisms are implicated, resulting in a wide range of clinical presentations. Understanding the specific mechanisms and risk factors involved in long COVID is crucial for tailoring effective interventions and support strategies. Management approaches involve comprehensive biopsychosocial assessments and treatment of symptoms and comorbidities, such as autonomic dysfunction, as well as multidisciplinary rehabilitation. The overall course of long COVID is one of gradual improvement, with recovery observed in the majority, though not all, of patients. As the research on long-COVID continues to evolve, ongoing studies are likely to shed more light on the intricate relationship between chronic diseases, such as oncological status, cardiovascular diseases, psychiatric disorders, and the persistent effects of SARS-CoV-2 infection. This information could guide healthcare providers, researchers, and policymakers in developing targeted interventions. Full article
(This article belongs to the Special Issue COVID-19 and Global Chronic Disease 2024: The Post-pandemic Era)
Show Figures

Figure 1

Back to TopTop